GlassScriptPhysician profile
Stanford D Gittlen
NPI 1124133590
$3,036.20
in general payments reported to CMS, 2019-2025
29 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $367 · 2021: $319 · 2022: $591 · 2023: $256 · 2024: $160 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $790.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $368.86 | 2019-2023 | Fasenra, Tagrisso |
| Insmed, INC. | $366.72 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $283.61 | 2019-2023 | Uptravi, Opsumit |
| Sunovion Pharmaceuticals INC. | $187.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $165.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.38 | 2019-2022 | |
| Pfizer INC. | $129.62 | 2020-2025 | |
| Genzyme Corporation | $82.69 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $57.54 | 2019 | |
| Shire North American Group INC | $43.99 | 2019 | |
| Abbvie INC. | $38.76 | 2022 | |
| United Therapeutics Corporation | $36.71 | 2019-2020 | |
| Genentech USA, INC. | $30.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $28.86 | 2019-2025 | Keytruda |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $28.17 | 2019 | |
| Csl Behring | $24.26 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.58 | 2019 | |
| Electromed, INC. | $20.10 | 2019 | |
| Vapotherm INC | $18.46 | 2021 | |
| Circassia INC. | $17.47 | 2019 | |
| Resmed Corp | $16.59 | 2020 | |
| Karyopharm Therapeutics INC. | $16.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2020 | |
| Medtronic, INC. | $14.98 | 2021 | |
| La Jolla Pharmaceutical Company | $14.90 | 2019 | |
| Breathe Technologies, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanford Gittlen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.